<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of gastroesophageal reflux disease in children and adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of gastroesophageal reflux disease in children and adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of gastroesophageal reflux disease in children and adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Harland S Winter, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            B UK Li, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 22, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The passage of gastric contents into the esophagus (gastroesophageal reflux [GER]) is a normal physiologic process that occurs in healthy infants, children, and adults. Most episodes are brief and do not cause symptoms, esophageal injury, or other complications. In contrast, GER disease (GERD) occurs when the reflux episodes are associated with symptoms or complications. The type of symptoms and complications of GERD in children vary with the child's age.
        </p>
        <p>
         Several treatment options are available for controlling symptoms and preventing complications in children with GERD. The choice among them depends on the patient's age, type and severity of symptoms, and response to treatment.
        </p>
        <p>
         This topic review focuses on the management of GERD in children and adolescents. Other topic reviews relevant to GER and GERD in the pediatric age group are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5892.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5876.html" rel="external">
          "Gastroesophageal reflux in infants"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4961.html" rel="external">
          "Gastroesophageal reflux in premature infants"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These discussions are generally consistent with the consensus guideline issued by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) [
         <a href="#rid1">
          1
         </a>
         ], and the American Academy of Pediatrics (AAP) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3880413540">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following definitions are used in this topic review, consistent with the guideline [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastroesophageal reflux (GER)
         </strong>
         – The passage of gastric contents into the esophagus, with or without regurgitation and vomiting
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastroesophageal reflux disease (GERD)
         </strong>
         – GER that leads to troublesome symptoms and/or complications
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Erosive esophagitis
         </strong>
         – Esophageal inflammation that leads to erosions that are visible at endoscopy
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1911817761">
         <span class="h1">
          REFERRALS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastroenterology
         </strong>
         – We suggest referral to a pediatric gastroenterologist in the following circumstances, consistent with the guideline [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alarm signs or symptoms that suggest an underlying disease, including unexplained weight loss, persistent forceful vomiting, dysphagia or odynophagia or hematemesis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         GERD symptoms that are refractory to treatment (ie, little or no symptomatic response to optimal treatment by eight weeks).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Endoscopically confirmed GERD that requires chronic treatment with acid-suppressing medication, ie, the patient cannot be permanently weaned from acid-suppressing medications within 6 to 12 months, despite repeated attempts.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonology or otolaryngology
         </strong>
         – Patients with unexplained chronic respiratory symptoms, chronic cough, or unexplained hoarseness usually should be evaluated first by a pulmonologist or otolaryngologist. The specialty evaluation typically includes a focused history, examination, chest radiograph, and spirometry. (See
         <a class="medical medical_review" href="/z/d/html/6343.html" rel="external">
          "Approach to chronic cough in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6304.html" rel="external">
          "Hoarseness in children: Evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2408719548">
         <span class="h1">
          TREATMENT APPROACH BY PRESENTING SYMPTOMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Definite indications for treatment of GERD are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heartburn (distinct and recurrent symptoms) (see
         <a class="local">
          'Heartburn'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Esophagitis (documented on endoscopy) (see
         <a class="local">
          'Esophagitis'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         By contrast, extraesophageal disease (asthma or pneumonia) usually has causes other than GERD. Treatment for GERD is appropriate only for selected patients. (See
         <a class="local">
          'Extraesophageal manifestations of GERD'
         </a>
         below.)
        </p>
        <p>
         The treatment approach for each of these presenting symptoms is outlined in the following sections, followed by a more detailed discussion of each type of intervention. (See
         <a class="local">
          'Lifestyle changes'
         </a>
         below and
         <a class="local">
          'Pharmacotherapy'
         </a>
         below and
         <a class="local">
          'Surgery'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1154332145">
         <span class="h2">
          Heartburn
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with both heartburn and alarm symptoms (dysphagia, weight loss, odynophagia, hematemesis, or recurrent forceful vomiting) should be referred to a gastroenterologist for further evaluation, which may include upper endoscopy.
        </p>
        <p>
         For patients with typical esophageal symptoms (eg, heartburn, increased salivation, retrosternal or epigastric discomfort, and no alarm symptoms), we recommend a "step-up" approach, starting with conservative options and progressing to more intensive therapy if needed  (
         <a class="graphic graphic_algorithm graphicRef117377" href="/z/d/graphic/117377.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild
         </strong>
         – For children and adolescents with mild or infrequent heartburn (averaging once a week or less), we suggest a trial of lifestyle changes (weight management for overweight patients; cessation of smoking and vaping and avoidance of tobacco smoke; head of bed elevation; and avoidance of chocolate, caffeine, spicy foods, alcohol, and other foods that exacerbate symptoms). Occasional use of antacids or histamine type 2 receptor antagonists (H2RAs) is acceptable for short-term relief of symptoms, but frequent use of these drugs (more than once/week) calls for advancement of therapy [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="local">
          'Lifestyle changes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate or severe
         </strong>
         – If the heartburn symptoms are moderate or severe, or fail to respond to lifestyle changes, we recommend a trial of acid-suppression therapy. For this trial, we typically use a proton pump inhibitor (PPI). An H2RA is a reasonable alternative but may be limited by the possibility of tachyphylaxis that can occur during a typical trial duration of four to eight weeks [
         <a href="#rid1">
          1,3
         </a>
         ]. If symptoms do not improve, or recur after stopping treatment, the patient should be evaluated by a pediatric gastroenterologist. If an H2RA is used initially and there is no improvement or partial improvement in two to four weeks, or if long-term treatment is required, therapy should be advanced to a PPI. (See
         <a class="local">
          'Pharmacotherapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         For neurologically impaired children with symptoms consistent with GERD, empiric treatment with acid-suppressing medications, usually a PPI, is appropriate because GERD is common in this population [
         <a href="#rid4">
          4
         </a>
         ]. However, if long-term pharmacotherapy is planned, endoscopy should be performed to evaluate for esophagitis. (See
         <a class="local">
          'Pharmacotherapy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5892.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents", section on 'Endoscopy and histology'
         </a>
         .)
        </p>
        <p>
         Children with autism spectrum disorder who are nonverbal often present with nonspecific, atypical signs and symptoms, including food refusal, chest tapping, pica, chewing on objects, and/or excessive salivation. (See
         <a class="medical medical_review" href="/z/d/html/627.html" rel="external">
          "Autism spectrum disorder in children and adolescents: Clinical features"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3704036010">
         <span class="h2">
          Esophagitis
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment strategy
         </strong>
         – For patients with endoscopically documented esophagitis, we employ a "step down" approach, in which we treat with a PPI for 8 to 12 weeks, then withdraw treatment as tolerated, or extend treatment if necessary  (
         <a class="graphic graphic_algorithm graphicRef117378" href="/z/d/graphic/117378.html" rel="external">
          algorithm 2
         </a>
         ). We suggest using a PPI because this class of medication is more effective than H2RAs for initial healing of esophagitis [
         <a href="#rid1">
          1,2
         </a>
         ]. Dosing and adverse effects are outlined in the table  (
         <a class="graphic graphic_table graphicRef55435" href="/z/d/graphic/55435.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Proton pump inhibitors'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow up
         </strong>
         – Further evaluation and treatment of patients with esophagitis depends on the severity of the esophagitis at baseline and on the degree of symptom relief with treatment. The histologic findings and differential diagnosis of esophagitis, and grading of erosive esophagitis are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2265.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux in adults", section on 'Endoscopic findings'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5892.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents", section on 'Endoscopy and histology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with only mild esophagitis (eg, histologic findings consistent with GERD but no grossly visible findings) can be treated for four to eight weeks and reassessed based on the degree of symptom relief.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with peptic erosive esophagitis at baseline should undergo a repeat endoscopy after three to six months of treatment; the repeat endoscopy is important to demonstrate healing and also to identify the possibility of stricture.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Distinguishing peptic esophagitis (ie, esophagitis caused by acid reflux) from eosinophilic esophagitis (EoE) may be difficult because both disorders are characterized by esophageal eosinophilia, and they may have similar symptoms. However, in peptic esophagitis the inflammation is usually greatest in the distal esophagus, and in EoE the number of eosinophils often exceeds 15 per high-power field. Six to eight biopsies from different areas of the esophagus are recommended [
         <a href="#rid5">
          5,6
         </a>
         ]. Esophagitis and symptoms that persist despite several months of effective acid suppression also should raise suspicion for EoE. (See
         <a class="medical medical_review" href="/z/d/html/2243.html" rel="external">
          "Clinical manifestations and diagnosis of eosinophilic esophagitis (EoE)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When continuous therapy is necessary to control symptoms, we suggest treatment with a PPI; however, H2RAs are a reasonable choice for brief or intermittent treatment [
         <a href="#rid1">
          1
         </a>
         ]. Long-term treatment with PPIs is sometimes necessary but should be undertaken for clear indications and with caution due to potential long-term side effects (see
         <a class="local">
          'Safety'
         </a>
         below). If the symptoms are well controlled, a trial of discontinuing treatment should be performed every three to six months, unless the patient has either a history of severe and recurrent esophagitis, or the endoscopy demonstrates Barrett esophagus (replacement of the normal squamous epithelium with metaplastic columnar epithelium). Long-term treatment with acid-suppressing medications is appropriate if symptoms or endoscopy indicate chronic or recurrent esophagitis, without evidence for EoE; such patients should be managed by a pediatric gastroenterologist, if possible. (See
         <a class="local">
          'Discontinuing proton pump inhibitors'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2236.html" rel="external">
          "Barrett's esophagus: Surveillance and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3828072732">
         <span class="h2">
          Dysphagia or odynophagia
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with dysphagia (difficulty swallowing) or odynophagia (pain with swallowing), empiric treatment for reflux (lifestyle changes or pharmacotherapy) is
         <strong>
          not
         </strong>
         recommended unless other causes of the symptoms have been excluded. Instead, these patients should have a careful diagnostic evaluation including upper endoscopy.
        </p>
        <p>
         Dysphagia may be caused by GERD but also may be due to other causes, such as EoE, pill-induced esophagitis (direct mucosal injury from swallowed medications, such as
         <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">
          tetracycline
         </a>
         that remain in the esophagus causing ulceration), esophageal dysmotility (eg, achalasia), or foreign body. Pill esophagitis is also an important cause of odynophagia; other causes include infectious esophagitis caused by cytomegalovirus, herpes, or
         <em>
          Candida
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/5892.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents", section on 'Dysphagia or odynophagia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H766122190">
         <span class="h2">
          Rumination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children who do not respond to conventional treatment for GERD should be evaluated for rumination. A small study of children with refractory GERD reported that 44 percent met criteria for rumination, but interpretation of these findings is limited because the study used novel high-resolution impedance indices to diagnose rumination rather than the standard antroduodenal manometry. Reflux events in patients with rumination were more likely to occur in the proximal esophagus, were often nonacidic, occurred more often postprandially, and were highly associated with symptoms [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5902.html" rel="external">
          "Approach to the infant or child with nausea and vomiting", section on 'Rumination syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3468458163">
         <span class="h2">
          Extraesophageal manifestations of GERD
         </span>
        </p>
        <p class="headingAnchor" id="H3463749930">
         <span class="h3">
          Asthma with gastroesophageal reflux
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          With GERD symptoms
         </strong>
         – For patients with persistent moderate to severe asthma (particularly, nocturnal wheezing)
         <strong>
          and clear symptoms
         </strong>
         suggesting GERD, including frequent heartburn or regurgitation, we suggest a trial of effective acid suppression for four to eight weeks [
         <a href="#rid1">
          1
         </a>
         ]. Management after the trial depends on the response. (See
         <a class="medical medical_review" href="/z/d/html/571.html" rel="external">
          "Gastroesophageal reflux and asthma", section on 'Empiric therapy in patients with symptomatic GERD'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This empiric approach to treatment is appropriate because although gastroesophageal reflux (GER) is an established trigger for asthma in many patients, it is difficult to predict which patients will respond to treatment [
         <a href="#rid8">
          8
         </a>
         ]. In approximately 60 percent of children with asthma and clinical or laboratory evidence of GER, asthma control will improve with effective treatment for reflux [
         <a href="#rid9">
          9
         </a>
         ]. In adults with GERD symptoms and moderate to severe asthma (or nocturnal asthma), randomized controlled trials of PPIs demonstrated small but significant improvements in numbers of asthma exacerbations. (See
         <a class="medical medical_review" href="/z/d/html/571.html" rel="external">
          "Gastroesophageal reflux and asthma", section on 'Evidence that GERD treatment improves asthma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Without GERD symptoms
         </strong>
         – A trial of acid-suppressing medication is generally
         <strong>
          not
         </strong>
         recommended for children or adults with asthma in the absence of GERD symptoms [
         <a href="#rid1">
          1
         </a>
         ]. However, in some patients with asthma, GERD may be silent and diagnosed only with esophageal pH-impedance monitoring (pH-MII). Thus, pH-MII or an empiric trial of antireflux treatment is reasonable in selected patients with asthma who are difficult to control (steroid-dependent) and/or have nocturnal onset of asthma, even in the absence of apparent symptoms of GERD. Other causes of wheezing should be carefully excluded, including foreign body aspiration. (See
         <a class="medical medical_review" href="/z/d/html/5892.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents", section on 'Asthma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5752.html" rel="external">
          "Evaluation of wheezing in infants and children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Antireflux surgery (fundoplication) is generally
         <strong>
          not
         </strong>
         recommended as a treatment for asthma that is thought to be related to GERD. Evidence to support the efficacy, patient selection, and role of antireflux surgery for patients with asthma and GERD is inadequate [
         <a href="#rid10">
          10
         </a>
         ]. Moreover, outcomes following fundoplication in children with asthma have a low rate of success, and as many as 75 percent of children continue to need acid-suppressing medications following surgery [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1977326370">
         <span class="h3">
          Recurrent pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         When aspiration and recurrent pneumonia are strongly suspected to be related to GERD, aggressive treatment is appropriate to prevent chronic progression of pulmonary disease [
         <a href="#rid1">
          1,11
         </a>
         ]. If pulmonary disease is mild, medical treatment with acid suppression can be used; pulmonary function should be carefully monitored in follow-up.
        </p>
        <p>
         There are no definitive tests to determine whether GERD is the cause of recurrent pneumonia in a given patient. Clinical decisions must be based on an individual patient's clinical risk and a combination of tests for GER, aspiration, and immune deficiency. The possibility of antegrade aspiration (aspiration during swallowing) should be fully investigated because this is a more common cause of recurrent pneumonia than retrograde aspiration (GERD). If the pneumonia is consistently in the same region of the lung, the patient should be evaluated for a rare H-type tracheoesophageal fistula. (See
         <a class="medical medical_review" href="/z/d/html/14537.html" rel="external">
          "Aspiration due to swallowing dysfunction in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5892.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents", section on 'Recurrent pneumonia'
         </a>
         .)
        </p>
        <p>
         If pulmonary disease is severe or progressive, transpyloric feeding or surgical treatment with fundoplication should be considered, but the success rate of fundoplication for treating pulmonary disease is poor [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Surgery'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3682138609">
         <span class="h3">
          Other extraesophageal symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         GERD is not a common cause of isolated chronic cough in children, except in those with neurologic abnormalities predisposing to aspiration; however, whether GERD causes cough remains unknown [
         <a href="#rid12">
          12
         </a>
         ]. Stridor, hoarseness, sinusitis, and otitis media have been associated with GERD, mostly in case reports and case series in children. Neither the association with GER nor the benefits of antisecretory therapy have been established [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5892.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents", section on 'Chronic cough'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5892.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents", section on 'Other conditions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3562965912">
         <span class="h1">
          MEDICAL TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h2">
          Lifestyle changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest lifestyle changes as an initial approach to treatment for children and adolescents with mild or infrequent symptoms of gastroesophageal reflux (GER), such as occasional heartburn or painless regurgitation. Lifestyle changes also may be helpful as an adjunct to pharmacologic treatment in patients with moderate or severe symptoms suggestive of GERD, or with documented esophagitis.
        </p>
        <p>
         The type of lifestyle changes that may be beneficial depend on the patient's age and symptom characteristics. An empiric approach is appropriate since there is little evidence that one of these approaches is more effective than others. Because few studies have examined the efficacy of lifestyle modifications in children and adolescents with GERD [
         <a href="#rid1">
          1
         </a>
         ], recommendations are mostly extrapolated from studies in adults. Even in adults, there is limited evidence supporting efficacy for these interventions. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults", section on 'Lifestyle and dietary modification'
         </a>
         .)
        </p>
        <p>
         The following approaches have some benefit in adult patients with reflux, but have not been rigorously evaluated in children [
         <a href="#rid1">
          1,13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight loss or weight management for individuals who are overweight [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Head of bed elevation and left lateral positioning – This is important for individuals with nocturnal or laryngeal symptoms, but its value for other situations is unclear. A trial of positional therapy is reasonable for children with symptoms of GERD but is not recommended for sleeping infants [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The following lifestyle approaches also are used frequently. The efficacy of these measures for managing symptoms is inconsistent, but there is some evidence that they improve laboratory measures of reflux (such as lower esophageal sphincter pressure) [
         <a href="#rid1">
          1,13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dietary modification – Sensitivity to dietary triggers varies among individuals. Therefore, dietary restriction should be limited to those foods that are associated with symptoms in a specific patient, as determined by trials of individual foods. Options include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoid foods that tend to induce reflux by reducing lower esophageal sphincter pressure, including chocolate, peppermint, and caffeinated beverages.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoid acidic foods, including colas, orange juice, and tomato sauce. Although their contribution to gastric acidity is probably minimal, ingestion of these foods seems to exacerbate symptoms in some patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoid high-fat foods in selected patients. This strategy is recommended in adults with GERD because fatty foods tend to slow gastric emptying and thereby promote reflux; however, the benefit of reducing fat intake in children is unproven. Decisions about whether to restrict dietary fat depend on the infant or child's overall nutritional status and the clinical response.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Positioning – Avoid the supine position soon after eating.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Salivation – Promote salivation by either chewing gum or using oral lozenges. Salivation neutralizes refluxed acid, thereby increasing the rate of esophageal acid clearance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcohol, tobacco, and vaping – Avoid alcohol and tobacco (including passive exposure to tobacco smoke). Substances that contain nicotine reduce lower esophageal sphincter pressure, and smoking also diminishes salivation [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Lifestyle modifications also are used to manage GER in infants, including changes in feeding, positioning, and avoidance of tobacco smoke and nicotine exposure. These approaches are discussed in detail in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5876.html" rel="external">
          "Gastroesophageal reflux in infants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4961.html" rel="external">
          "Gastroesophageal reflux in premature infants"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Pharmacotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drugs that are used for treatment of GERD can be grouped into the following categories  (
         <a class="graphic graphic_table graphicRef55435" href="/z/d/graphic/55435.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Proton pump inhibitors (PPIs)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Histamine type 2 receptor antagonists (H2RAs)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antacids
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surface agents
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prokinetics
        </p>
        <p>
        </p>
        <p>
         The experience with each of these categories of drugs in children and adolescents is detailed in the following sections. Pharmacotherapy for GER in adults is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Proton pump inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPIs block acid secretion by irreversibly binding to and inhibiting the hydrogen-potassium ATPase pump that resides on the luminal surface of the parietal cell membrane. The drugs in this class include
         <a class="drug drug_pediatric" data-topicid="12658" href="/z/d/drug information/12658.html" rel="external">
          omeprazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12543" href="/z/d/drug information/12543.html" rel="external">
          lansoprazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13098" href="/z/d/drug information/13098.html" rel="external">
          rabeprazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12677" href="/z/d/drug information/12677.html" rel="external">
          pantoprazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13281" href="/z/d/drug information/13281.html" rel="external">
          esomeprazole
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="130777" href="/z/d/drug information/130777.html" rel="external">
          dexlansoprazole
         </a>
         . The differences in efficacy among drugs in this class appear to be small and of uncertain clinical significance; thus, it is reasonable to make treatment decisions based on cost and on which dosing formulation is easiest to administer to the child. Aspects of the pharmacology of PPIs and their efficacy in adults are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Pharmacology'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12658" href="/z/d/drug information/12658.html" rel="external">
          Omeprazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13281" href="/z/d/drug information/13281.html" rel="external">
          esomeprazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12543" href="/z/d/drug information/12543.html" rel="external">
          lansoprazole
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="130777" href="/z/d/drug information/130777.html" rel="external">
          dexlansoprazole
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12677" href="/z/d/drug information/12677.html" rel="external">
          pantoprazole
         </a>
         have been most extensively studied in children and are approved by the US Food and Drug Administration (FDA) for this age group [
         <a href="#rid1">
          1
         </a>
         ]. Approval updates and labeling changes are available on the FDA website [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h4">
          Indications and efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evidence for efficacy of PPIs depends on the patient population:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Esophagitis or marked GERD symptoms
         </strong>
         – For treatment of endoscopy-proven peptic esophagitis and esophagitis-associated symptoms, we suggest use of a PPI rather than an H2RA. This suggestion is primarily based on randomized studies in adults, which demonstrated that PPIs are effective and superior to H2RAs [
         <a href="#rid1">
          1,16
         </a>
         ]. Compared with H2RAs, PPIs produce a greater reduction in acid secretion, have a longer duration of action, and tolerance does not develop. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our suggestion that PPIs be selected in preference to other forms of acid suppression in patients with documented esophagitis is based on extrapolation from studies in adults, and a few clinical trials in children, as well as observations that tachyphylaxis (loss of response) tends to occur with H2RAs [
         <a href="#rid17">
          17
         </a>
         ]. In addition, there may be better compliance with PPIs that can be given once daily as compared with multiple-dose regimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of PPIs for treating esophagitis or heartburn in children and adolescents is based on limited evidence [
         <a href="#rid18">
          18
         </a>
         ]. Several case series report that PPIs have healed severe esophagitis that had been unresponsive to H2RAs [
         <a href="#rid11">
          11,19
         </a>
         ]. The only controlled trials compare PPIs with alternate forms of acid suppression. These demonstrated that PPIs were as effective as H2RAs for initial treatment of esophagitis [
         <a href="#rid20">
          20
         </a>
         ], marked GERD symptoms [
         <a href="#rid21">
          21
         </a>
         ], or maintenance of remission after initial treatment with PPIs [
         <a href="#rid22">
          22
         </a>
         ]. The superiority of PPIs over H2RAs is largely based on indirect evidence that PPIs are more effective for reducing gastric acidity and that H2RAs become less effective over time (tachyphylaxis) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asthma and other GERD manifestations
         </strong>
         – The benefit of PPIs on extraesophageal manifestations of GERD in children, such as asthma, has not been well studied, although they are used for this purpose in children based on data in adults. (See
         <a class="local">
          'Asthma with gastroesophageal reflux'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/571.html" rel="external">
          "Gastroesophageal reflux and asthma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infants
         </strong>
         – Several randomized trials and a systematic review concluded that PPIs are
         <strong>
          not
         </strong>
         beneficial in infants with irritability or regurgitation, because they do not improve symptoms as compared with placebo [
         <a href="#rid23">
          23-26
         </a>
         ]. However, PPIs or other acid-suppressing regimens are appropriate for an infant with moderate or severe esophagitis on endoscopic biopsies, a rare occurrence in this age group. (See
         <a class="medical medical_review" href="/z/d/html/5876.html" rel="external">
          "Gastroesophageal reflux in infants", section on 'Pharmacotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h4">
          Dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dosing guidelines for PPIs vary considerably; typical doses are outlined in the table  (
         <a class="graphic graphic_table graphicRef55435" href="/z/d/graphic/55435.html" rel="external">
          table 1
         </a>
         ). Infants and younger children appear to metabolize PPIs more rapidly and may require higher per-kilogram dosing than older individuals [
         <a href="#rid1">
          1,27,28
         </a>
         ]. In pediatric studies, effective doses of
         <a class="drug drug_pediatric" data-topicid="12658" href="/z/d/drug information/12658.html" rel="external">
          omeprazole
         </a>
         ranged from 0.3 to 3.5 mg/kg/day (maximum 80 mg/day) and doses of
         <a class="drug drug_pediatric" data-topicid="12543" href="/z/d/drug information/12543.html" rel="external">
          lansoprazole
         </a>
         ranged from 0.73 to 1.66 mg/kg/day (maximum 30 mg/day) [
         <a href="#rid29">
          29
         </a>
         ]. However, there is little evidence to support doses of omeprazole over 40 mg daily for children, even for the treatment of endoscopically documented esophagitis. Some children may require twice-daily dosing to achieve optimal acid suppression; we suggest starting with once-daily dosing and advancing to twice-daily dosing if there is breakthrough of symptoms. Some providers alternate doses of a PPI with an H2RA, but there is no specific evidence supporting this practice.
        </p>
        <p>
         For infants who require acid suppression (eg, due to documented esophagitis), higher doses might be needed to achieve adequate levels of acid suppression, due to differences in pharmacokinetics in infants compared with older children. (See
         <a class="medical medical_review" href="/z/d/html/5876.html" rel="external">
          "Gastroesophageal reflux in infants", section on 'Pharmacotherapy'
         </a>
         .)
        </p>
        <p>
         The duration of therapy is four to eight weeks for moderate to severe heartburn and up to 12 weeks for documented esophagitis. If the esophagitis is severe (erosive), PPI treatment may be prolonged for three to six months, followed by repeat endoscopy to assess for healing. (See
         <a class="local">
          'Esophagitis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults", section on 'Proton pump inhibitors'
         </a>
         .)
        </p>
        <p>
         The form of drug is important when choosing a PPI for children, for whom swallowing a capsule can be difficult. Several of these drugs are formulated as capsules containing enteric-coated granules that can be sprinkled onto soft foods (eg, applesauce), dissolvable tablets that can be placed on the tongue or dissolved in water, or powder packets that can be dissolved or compounded and flavored in a suspension.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h4">
          Safety
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although PPIs are generally well tolerated, long-term studies have raised concerns that long-term treatment with PPIs is associated with increased risk for some infectious, metabolic, and nutritional disorders. Most data on the long-term safety of PPIs are from studies in adults.
        </p>
        <p>
         Potential safety concerns based on case-control studies in infants and children suggest an increased risk of necrotizing enterocolitis, pneumonia, upper respiratory tract infections, sepsis, urinary tract infections,
         <em>
          Clostridioides
         </em>
         <em>
          difficile
         </em>
         infections, and fractures [
         <a href="#rid1">
          1,30,31
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infectious complications – In 2012, the FDA issued a
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwayback.archive-it.org%2F7993%2F20170112164921%2Fhttp%3A%2F%2Fwww.fda.gov%2FSafety%2FMedWatch%2FSafetyInformation%2FSafetyAlertsforHumanMedicalProducts%2Fucm290838.htm&amp;token=B5bdo9kEWylbELsQrJIsgjeU%2FaBDolG%2ByUK3Y0azkpL%2BGaceovcDQu%2FBVEH1srP1EoCBIzX5tk3HGOVUgw%2FsgRMn83ut39rh79E3N3Y1kvf315fxKmeaEy2vaK%2Bhhmzjp5vewZR0fzKbNb0635eVIpa0J6N8PhTRtqrmZKmlEhka2z2uxapup0DpWYjfcWEQ&amp;TOPIC_ID=5900" target="_blank">
          Safety Alert
         </a>
         about the association of PPI treatment with
         <em>
          C
         </em>
         .
         <em>
          difficile
         </em>
         and encouraged providers to consider the possibility of
         <em>
          C
         </em>
         .
         <em>
          difficile
         </em>
         -associated diarrhea in PPI users with persistent diarrhea [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6041.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in children: Microbiology, pathogenesis, and epidemiology", section on 'Other risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other possible infectious complications of PPIs include community-acquired pneumonia [
         <a href="#rid33">
          33,34
         </a>
         ] and small intestine bacterial overgrowth [
         <a href="#rid35">
          35
         </a>
         ] and others [
         <a href="#rid31">
          31
         </a>
         ]. A possible explanation for the infectious complications is supplied by a study reporting that treatment with acid-suppressing medications was associated with gastric bacterial overgrowth [
         <a href="#rid36">
          36
         </a>
         ]. Moreover, patients on acid-suppressing medications who experienced significant nonacid reflux also had higher bacterial concentrations in the lungs. (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Gastrointestinal effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Pneumonia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malabsorption and bone health – Other safety concerns include malabsorption of vitamin
         <sub>
         </sub>
         B12, iron, and magnesium [
         <a href="#rid37">
          37,38
         </a>
         ]. Concerns about long-term effects on bone metabolism have been raised based on studies in adults. Several studies reported an association between PPI use during infancy and subsequent fractures during childhood [
         <a href="#rid39">
          39-41
         </a>
         ]. Although the effect size is small, the finding is consistent with studies in adults showing an association between PPI use and osteoporotic fractures [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2036.html" rel="external">
          "Drugs that affect bone metabolism", section on 'Proton pump inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other concerns about the safety of PPIs have been raised but are not well supported by available data. A theoretical concern for gastric carcinoid tumors or colon cancer was raised because of the observation that long-term use of PPIs may increase serum gastrin levels and induce mild enterochromaffin cell hyperplasia and/or atrophic gastritis. However, no increased risk for cancer has been shown in studies in adults treated with PPIs for up to 11 years [
         <a href="#rid43">
          43
         </a>
         ] or children treated for a median 2.8 years [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Hypergastrinemia'
         </a>
         .)
        </p>
        <p>
         Limited data in adults have raised the possibility of an association between PPI use and nephritis, chronic kidney disease or food allergy. (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Kidney disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2408.html" rel="external">
          "Pathogenesis of food allergy", section on 'Acid blockade'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H406045">
         <span class="h4">
          Discontinuing proton pump inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the safety concerns described above, patients treated with PPIs should be reevaluated on a regular basis to determine if ongoing use is necessary. Patients who have ongoing symptoms after four to eight weeks of PPI therapy should be reevaluated for treatment adherence and to exclude other causes of the symptoms [
         <a href="#rid1">
          1
         </a>
         ]. If long-term PPI therapy is undertaken, our practice is to attempt to wean patients from PPIs after six months of treatment and then periodically thereafter, depending on symptom control.
        </p>
        <p>
         Stopping PPIs may be associated with acid rebound, in which discontinuation causes a temporary increase in gastric acid output to levels higher than at baseline, with a corresponding rebound of reflux-related symptoms during the first few weeks after discontinuation of the PPI [
         <a href="#rid45">
          45
         </a>
         ]. The optimal management strategy to minimize problems with acid rebound has not been established. When attempting to discontinue PPIs in patients treated chronically, our practice is to gradually taper PPIs to minimize the potential problem of acid rebound (eg, stepwise reduction in dose over two to four weeks), although there is no clinical evidence that this approach improves the likelihood of successful weaning. In particular, a study of this type of tapering regimen in adults failed to establish a clinical benefit [
         <a href="#rid46">
          46
         </a>
         ]. An alternate approach is to wean the patient initially to an H2RA. The evidence for acid rebound is from studies in adults and is described in detail in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Discontinuing PPIs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Histamine type 2 receptor antagonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with mild or intermittent symptoms of GERD that do not respond to lifestyle changes, we suggest a trial of H2RAs rather than PPIs or other drugs. Commonly used H2RAs and doses are outlined in the table  (
         <a class="graphic graphic_table graphicRef55435" href="/z/d/graphic/55435.html" rel="external">
          table 1
         </a>
         ). H2RAs have moderate effects on GER, as measured by relief of symptoms and mucosal healing, but because they have a relatively rapid onset of action, they are well suited for providing symptomatic relief. However, they are somewhat less effective than the PPI class, especially for chronic use [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The H2RAs inhibit acid secretion by blocking histamine H2 receptors on the parietal cell. The H2RAs are available in the United States, in both prescription strength and a lower strength for nonprescription (over-the-counter) sales are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">
          Cimetidine
         </a>
         (Tagamet)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13295" href="/z/d/drug information/13295.html" rel="external">
          Famotidine
         </a>
         (Pepcid)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12649" href="/z/d/drug information/12649.html" rel="external">
          Nizatidine
         </a>
         (Axid)
        </p>
        <p>
        </p>
        <p>
         Multiple controlled trials in adults have evaluated the efficacy of H2RAs in adults [
         <a href="#rid16">
          16
         </a>
         ]. These studies have shown that H2RAs are superior to placebo for healing esophagitis and improving symptoms, with little clinical difference among the formulations when dosed appropriately. However, their benefit is greatest for patients with mild esophagitis, and tolerance (tachyphylaxis) develops within days to a few weeks of beginning treatment, limiting efficacy for long-term management [
         <a href="#rid1">
          1,17
         </a>
         ]. H2RAs reach peak onset of action approximately 2.5 hours after dosing, and the duration of action is 4 to 10 hours, so they are useful for on-demand treatment of occasional symptoms, or for short-term continuous use. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults", section on 'Histamine 2 receptor antagonist'
         </a>
         .)
        </p>
        <p>
         Fewer studies have been performed in children, but the results are similar to the experience in adults [
         <a href="#rid47">
          47,48
         </a>
         ]. One randomized trial included 32 children (21 to 29 months) with esophagitis who were randomly assigned to receive
         <a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">
          cimetidine
         </a>
         (30 to 40 mg/kg per day) or placebo [
         <a href="#rid47">
          47
         </a>
         ]. After 12 weeks, healing was observed significantly more often in the cimetidine-treated group. Improvement of esophagitis was seen in all patients with mild or moderate esophagitis compared with only 57 percent of patients with severe esophagitis. In another small trial, children with dyspepsia and abdominal pain who were randomized to
         <a class="drug drug_pediatric" data-topicid="13295" href="/z/d/drug information/13295.html" rel="external">
          famotidine
         </a>
         experiences significant improvement in a subjective global pain assessment compared with placebo [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         The use of H2RAs is associated with an increased risk of enteric infection, particularly
         <em>
          C
         </em>
         .
         <em>
          difficile
         </em>
         and community-acquired pneumonia [
         <a href="#rid33">
          33
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/6041.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in children: Microbiology, pathogenesis, and epidemiology", section on 'Other risk factors'
         </a>
         ).
         <a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">
          Cimetidine
         </a>
         is a moderate inhibitor of cytochrome P450 (CYP) metabolism and can increase levels of some co-administered medications, such as
         <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">
          theophylline
         </a>
         , selective serotonin reuptake inhibitors,
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          warfarin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13159" href="/z/d/drug information/13159.html" rel="external">
          cisapride
         </a>
         (refer to the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included with UpToDate).
         <a class="drug drug_pediatric" data-topicid="13295" href="/z/d/drug information/13295.html" rel="external">
          Famotidine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12649" href="/z/d/drug information/12649.html" rel="external">
          nizatidine
         </a>
         do not inhibit CYP metabolism or alter levels of co-administered drugs metabolized by CYP. Of note,
         <a class="drug drug_pediatric" data-topicid="12759" href="/z/d/drug information/12759.html" rel="external">
          ranitidine
         </a>
         was withdrawn from the market in the United States in April 2020 because of concerns about contamination with N-Nitrosodimethylamine (NDMA) [
         <a href="#rid50">
          50
         </a>
         ]; low levels of NDMA contaminants have also been found in some nizatidine products [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Antacids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antacids should not be used chronically for treatment of GERD but are appropriate for short-term relief of heartburn in older children, adolescents, or adults with infrequent symptoms (less than once a week) [
         <a href="#rid1">
          1
         </a>
         ]. Antacids often begin to provide relief of heartburn within five minutes, but the duration of the effect is approximately 30 to 60 minutes. Chronic use of antacids is not recommended, due to safety concerns, especially in infants due to potential complications such as hypophosphatemic rickets or in children with renal disease [
         <a href="#rid1">
          1,52
         </a>
         ].
        </p>
        <p>
         Antacids work by neutralizing gastric pH and thereby decreasing the exposure of the esophageal mucosa to gastric acidity during episodes of reflux. Various preparations that are commercially available usually contain the combination of magnesium and
         <a class="drug drug_pediatric" data-topicid="13169" href="/z/d/drug information/13169.html" rel="external">
          aluminum hydroxide
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12569" href="/z/d/drug information/12569.html" rel="external">
          calcium carbonate
         </a>
         . At least two studies suggested that high-dose antacid therapy with magnesium/aluminum-containing acids was as effective as
         <a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">
          cimetidine
         </a>
         for the short-term treatment of esophagitis in children [
         <a href="#rid53">
          53,54
         </a>
         ].
        </p>
        <p>
         Aluminum-containing antacids can cause aluminum toxicity in infants or in individuals with renal failure. Aluminum toxicity is associated with complications such as osteopenia, microcytic anemia, and neurotoxicity [
         <a href="#rid55">
          55-58
         </a>
         ]. Magnesium-containing antacids can cause hypermagnesemia in patients with renal insufficiency. As a result, use of antacids generally is restricted to short-term relief of symptoms in older children and adolescents. The efficacy and safety of other types of antacids in children have not been well-studied. (See
         <a class="medical medical_review" href="/z/d/html/32.html" rel="external">
          "Antiulcer medications: Mechanism of action, pharmacology, and side effects", section on 'Antacids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Prokinetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prokinetic drugs are generally
         <strong>
          not
         </strong>
         recommended for management of GERD, because of significant safety concerns and limited efficacy [
         <a href="#rid1">
          1,4
         </a>
         ]. Systematic reviews have not supported the use of
         <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">
          metoclopramide
         </a>
         [
         <a href="#rid59">
          59
         </a>
         ],
         <a class="drug drug_pediatric" data-topicid="13159" href="/z/d/drug information/13159.html" rel="external">
          cisapride
         </a>
         [
         <a href="#rid60">
          60
         </a>
         ], or
         <a class="drug drug_general" data-topicid="8777" href="/z/d/drug information/8777.html" rel="external">
          domperidone
         </a>
         [
         <a href="#rid18">
          18,61
         </a>
         ] for treatment of GERD [
         <a href="#rid62">
          62
         </a>
         ]. These drugs should be considered for use only in carefully selected patients who have GERD along with delayed gastric emptying and in whom constipation has been ruled out as a confounding factor.
         <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">
          Erythromycin
         </a>
         also is used for patients with gastric dysmotility, such as postviral gastroparesis, but its use is limited by side effects and tachyphylaxis (tolerance). The use of these drugs for gastroparesis in adults is discussed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/2532.html" rel="external">
          "Treatment of gastroparesis"
         </a>
         .)
        </p>
        <p>
         A trial of
         <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">
          baclofen
         </a>
         may be appropriate in selected patients with refractory GERD, as an alternative to antireflux surgery [
         <a href="#rid1">
          1
         </a>
         ]. Baclofen is a gamma-amino-butyric acid B receptor agonist that inhibits the transient relaxations of the lower esophageal sphincter that are a predominant mechanism of GER. A limited body of evidence in adults and children suggests that baclofen reduces reflux symptoms after acute or chronic dosing, reduces the frequency of esophageal sphincter relaxation and esophageal acid exposure, and accelerates gastric emptying [
         <a href="#rid63">
          63-66
         </a>
         ]. Potential side effects include dyspepsia, drowsiness, and lowered seizure threshold [
         <a href="#rid1">
          1
         </a>
         ]. Because of side effects, baclofen is rarely used to treat GERD in children without underlying neurologic problems. Baclofen is occasionally used for children with cerebral palsy, primarily to improve spasticity. (See
         <a class="medical medical_review" href="/z/d/html/118855.html" rel="external">
          "Cerebral palsy: Treatment of spasticity, dystonia, and associated orthopedic issues", section on 'Oral antispasticity drugs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Surface agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surface agents work by creating a barrier that impedes acid peptic injury to mucosal surfaces. Only two such substances have been evaluated in the treatment of GERD:
         <a class="drug drug_pediatric" data-topicid="12811" href="/z/d/drug information/12811.html" rel="external">
          sucralfate
         </a>
         and sodium alginate. These agents are not recommended for chronic treatment of GERD in children, although they may be used for short-term management of symptoms in selected patients [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults", section on 'Surface agents and alginates'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12811" href="/z/d/drug information/12811.html" rel="external">
          Sucralfate
         </a>
         (aluminum sucrose sulfate) adheres to the damaged mucosal surface, promoting healing and protecting the surface from further peptic injury by mechanisms that are incompletely understood. A study in adults with nonerosive esophagitis found that it decreased symptoms and promoted healing [
         <a href="#rid67">
          67
         </a>
         ]. One controlled trial in children suggested that sucralfate was as effective as
         <a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">
          cimetidine
         </a>
         for treatment of esophagitis [
         <a href="#rid68">
          68
         </a>
         ]. However, because of short duration of action, concerns related to aluminum toxicity and limited efficacy as compared with PPIs, sucralfate has minimal, if any, role in the treatment of GERD in children or adults [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Sodium alginate, which is derived from seaweed, forms a surface gel that creates a physical barrier against regurgitation of gastric contents and protects the esophageal mucosa. Studies of its efficacy in improving symptoms and reducing esophageal acid exposure compared with other available treatments have produced conflicting results [
         <a href="#rid69">
          69-72
         </a>
         ]. It is not recommended for chronic treatment of GERD in children, due to lack of evidence for efficacy in low-quality clinical studies [
         <a href="#rid1">
          1
         </a>
         ]. A preparation available in the United States (Gaviscon) also contains an antacid and is used for the temporary relief of heartburn in adults [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2925126330">
         <span class="h3">
          Complementary and alternative medicine
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of herbal remedies are sometimes used for acid reflux or other gastrointestinal complaints, including chamomile, slippery elm, and ginger root [
         <a href="#rid74">
          74
         </a>
         ]. Many anecdotal reports suggest that these herbs sometimes improve symptoms, but no randomized trials are available to guide their use. Since many families seek and use these remedies, it is important to inquire about their use in an open, nonjudgmental fashion, and to review the specific remedies used for potential toxicities. The National Institutes of Health's
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nccih.nih.gov%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F%2FvRJTX6pAh9HqPuMIdRDLCvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=5900" target="_blank">
          National Center for Complementary and Integrative Health
         </a>
         provides reliable information on complementary and alternative medicine practices [
         <a href="#rid75">
          75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2851.html" rel="external">
          "Complementary and integrative health in pediatrics"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1392.html" rel="external">
          "Overview of herbal medicine and dietary supplements"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          SURGERY
         </span>
        </p>
        <p class="headingAnchor" id="H4062730848">
         <span class="h2">
          Gastrostomy placement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Placement of a percutaneous endoscopic gastrostomy (PEG) is often considered in neurologically impaired children with feeding problems, poor weight gain, and GERD. The PEG usually should be performed without fundoplication, followed by medical antireflux therapy if clinically indicated [
         <a href="#rid4">
          4,76
         </a>
         ]. This is because fundoplication increases the risk of complications and does not improve reflux-related outcomes [
         <a href="#rid77">
          77,78
         </a>
         ]. This was shown in a retrospective multiinstitutional study of infants with neurologic impairment who underwent PEG placement with or without fundoplication, which showed that fundoplication did not reduce hospital admissions for reflux-related problems during one-year follow-up [
         <a href="#rid77">
          77
         </a>
         ]. For the minority (5 to 29 percent) of patients who fail medical therapy, fundoplication can be performed as a second step [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         Another alternative to antireflux surgery is transpyloric or jejunal feeding (via nasojejunal or gastrojejunal feeding tubes, or surgical placement of a jejunal feeding ostomy), which reduce reflux by bypassing the stomach [
         <a href="#rid1">
          1
         </a>
         ]. The efficacy of this approach is variable, and its utility is limited by tube dislodgement and other practical considerations [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15643.html" rel="external">
          "Overview of enteral nutrition in infants and children", section on 'Poor gastric emptying or aspiration risk'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H685482048">
         <span class="h2">
          Fundoplication
         </span>
        </p>
        <p class="headingAnchor" id="H451760083">
         <span class="h3">
          Indications and presurgical evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antireflux surgery is sometimes indicated in patients with debilitating GERD that is refractory to medical management, after other causes of the symptoms have been excluded [
         <a href="#rid1">
          1,80
         </a>
         ]. Many candidates for antireflux surgery have underlying neurologic impairment such as cerebral palsy. Surgery should be approached with caution because indications for surgery have not been definitively established, estimates of efficacy and failure rates vary widely, and complications are common, as discussed below. (See
         <a class="local">
          'Efficacy'
         </a>
         below and
         <a class="local">
          'Complications'
         </a>
         below.)
        </p>
        <p>
         Candidates for surgery should be carefully evaluated to exclude other causes of the symptoms and signs. The diagnostic tests and surgical considerations depend on the patient's clinical presentation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intractable esophagitis
         </strong>
         – Children with chronic esophagitis unresponsive to acid suppression might be considered for antireflux surgery. They should first undergo a full evaluation to exclude other causes of esophageal inflammation, especially eosinophilic esophagitis (EoE). At a minimum, the evaluation should include upper endoscopy with biopsies and esophageal pH monitoring while on proton pump inhibitor (PPI) therapy, to confirm whether gastric acid was adequately suppressed. (See
         <a class="medical medical_review" href="/z/d/html/2243.html" rel="external">
          "Clinical manifestations and diagnosis of eosinophilic esophagitis (EoE)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary disease that is thought to be due to aspiration
         </strong>
         – In children with neurologic impairment and suspected aspiration, the possibility of anti-reflux surgery should be approached with caution. This is because it may be difficult to discriminate retrograde aspiration (due to GERD) from antegrade aspiration (due to swallowing dysfunction). Moreover, surgery has low success rates for preventing progression of pulmonary disease, as outlined below (see
         <a class="local">
          'Efficacy'
         </a>
         below). Although the fundoplication can reduce gastroesophageal reflux (GER), it can also impede esophageal clearance and increase the likelihood of aspiration. For this group of patients, alternative approaches to reducing aspiration should be considered, such as transpyloric feeding or gastrostomy. (See
         <a class="local">
          'Gastrostomy placement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The evaluation of patients suspected to have pulmonary disease related to GERD often includes review of all radiographic studies, swallowing studies, esophageal pH and impedance monitoring, polysomnography, and bronchoalveolar lavage. The combined results of all these studies should be interpreted by clinicians with experience in swallowing dysfunction because no single test can determine the role that GERD is playing in pulmonary disease. (See
         <a class="medical medical_review" href="/z/d/html/14537.html" rel="external">
          "Aspiration due to swallowing dysfunction in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5892.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3902144325">
         <span class="h3">
          Relative contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fundoplication is relatively contraindicated for individuals with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal dysmotility, recurrent vomiting or retching (rather than regurgitation/effortless reflux) – These individuals are at high risk for feeding intolerance and intractable retching after fundoplication [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurologic disability – These individuals tend to have poor outcomes after fundoplication, including retching, failure of the surgery (due to breakdown of the wrap), and other complications that may be life-threatening [
         <a href="#rid82">
          82-86
         </a>
         ]. Because they have impaired central inhibition, gastrointestinal dysmotility (impaired gastric accommodation) and visceral hypersensitivity may occur after fundoplication, activating the emetic reflex and causing breakdown of the wrap [
         <a href="#rid87">
          87,88
         </a>
         ]. Percutaneous gastrostomy feedings are an alternative approach to managing chronic GERD and poor feeding in these patients [
         <a href="#rid79">
          79
         </a>
         ]. (See
         <a class="local">
          'Gastrostomy placement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Although postoperative retching is particularly common in the above groups of patients, it can also occur in patients without these characteristics. (See
         <a class="local">
          'Complications'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Technique
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most commonly performed operation is a Nissen fundoplication. This procedure originally involved passage of the gastric fundus behind the esophagus to encircle up to 6 cm of the distal esophagus. However, many variations and modifications have been described, and a Nissen fundoplication may be performed differently by different surgeons  (
         <a class="graphic graphic_figure graphicRef51213" href="/z/d/graphic/51213.html" rel="external">
          figure 1
         </a>
         ). Variables include approach (transthoracic or abdominal); portion of stomach wall used (anterior and posterior or anterior only); combination with other procedures (eg, vagotomy or gastroplasty); as well as the tightness, the length, and the completeness (270º to 360º) of the wrap.
        </p>
        <p>
         The Nissen fundoplication is now performed laparoscopically at many centers. In experienced centers, short-term complication rates are similar for laparoscopic and the open techniques [
         <a href="#rid89">
          89
         </a>
         ]. Some studies suggest that laparoscopic surgery has fewer complications, such as retching [
         <a href="#rid90">
          90-93
         </a>
         ], while others report somewhat higher rates of reoperation and recurrence of GERD compared with open fundoplication [
         <a href="#rid94">
          94-96
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptom improvement has been described in approximately 60 to 90 percent of children undergoing fundoplication [
         <a href="#rid1">
          1
         </a>
         ], but "failure rates" (variously defined) vary widely among reports, ranging from 2 to 50 percent [
         <a href="#rid94">
          94,97
         </a>
         ]. As an example, in one study, nearly two-thirds of children had ongoing reflux requiring treatment two months following fundoplication; a majority of the subjects had neurodevelopmental delay [
         <a href="#rid98">
          98
         </a>
         ]. In studies that have reported longer-term outcomes, most demonstrate higher rates of failure within one to three years [
         <a href="#rid77">
          77,82
         </a>
         ]. Several studies suggest higher failure rates in children with neurologic impairment, chronic respiratory conditions, repaired esophageal atresia, and in infants [
         <a href="#rid1">
          1,94,99-101
         </a>
         ]. In particular, antireflux surgery has low success rates as an intervention for aspiration pneumonia [
         <a href="#rid1">
          1,77,102-104
         </a>
         ]. Similar unsatisfactory outcomes were seen in a report of children with cystic fibrosis and GERD [
         <a href="#rid105">
          105
         </a>
         ]. Nearly one-half of the children had ongoing symptoms of GERD after fundoplication, and overall there was little benefit to pulmonary function. Twelve percent of patients had complications that required a subsequent surgical procedure.
        </p>
        <p>
         The wide variation in efficacy estimates is likely due to the use of different inclusion criteria, with short follow-up periods and reported variable endpoints; many of these studies focused on neurologically impaired children [
         <a href="#rid93">
          93,98,99,106-110
         </a>
         ]. These limitations and the absence of controlled trials are critical impediments to defining the role of antireflux surgery in the long-term management of GERD in children.
        </p>
        <p>
         Experience in adults has demonstrated that patients who do not respond to adequate doses of medical therapy (particularly those with typical features of GERD, such as heartburn) also may have a poor response to surgery, questioning the role of antireflux surgery in patients with symptoms refractory to medical therapy. Furthermore, long-term follow-up of patients who underwent standard antireflux surgery reveals that even after surgery, many continue to depend on medical therapy to control symptoms. (See
         <a class="medical medical_review" href="/z/d/html/2278.html" rel="external">
          "Surgical treatment of gastroesophageal reflux in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complications of antireflux surgery range from 2 to 45 percent [
         <a href="#rid1">
          1,111-113
         </a>
         ]. The most common complications included breakdown of the wrap (1 to 13 percent), small bowel obstruction (1 to 11 percent), gas bloat syndrome (2 to 8 percent), infection (1 to 9 percent), atelectasis or pneumonia (4 to 13 percent), perforation (2 to 4 percent), persistent esophageal stricture (1 to 9 percent), and esophageal obstruction (1 to 9 percent). Complications that occurred less frequently included an incisional hernia, gastroparesis, and dumping syndrome. Reoperation was required in 3 to 19 percent of patients, and operative mortality ranged from 0 to 5 percent. The presenting symptoms of dumping syndrome are often irritability after feeds, diaphoresis, or diarrhea; management is described separately. (See
         <a class="medical medical_review" href="/z/d/html/2583.html" rel="external">
          "Enteral feeding: Gastric versus post-pyloric", section on 'Feeding intolerance'
         </a>
         .)
        </p>
        <p>
         Retching (dry heaves) is common in children who have undergone fundoplication, particularly children who are neurologically impaired [
         <a href="#rid94">
          94,114
         </a>
         ]. The presence of preoperative forceful vomiting (versus effortless regurgitation) is a significant predictor of the development of postoperative retching [
         <a href="#rid115">
          115
         </a>
         ]. Treatment for this complication is difficult, and, if the retching is not controlled, it may disrupt the surgical repair. The optimal treatment varies among patients, so a trial-and-error approach is appropriate. Options include modification of feeding content and route (including jejunal feeding), use of antiemetics and motility agents (
         <a class="drug drug_pediatric" data-topicid="13194" href="/z/d/drug information/13194.html" rel="external">
          cyproheptadine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">
          ondansetron
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="17055" href="/z/d/drug information/17055.html" rel="external">
          aprepitant
         </a>
         , alimemazine), neuromodulation, and other novel therapies (eg, tricyclic antidepressants, gabapentinoids, cannabinoids, acupuncture or vagal nerve/gastric electrical stimulation) [
         <a href="#rid81">
          81
         </a>
         ]. Most of these interventions are supported by only low-quality evidence (case series or expert opinion). Symptoms tend to improve after several months.
        </p>
        <p>
         Patients with neurologic impairment, obesity, or those requiring a second antireflux operation appear to have a somewhat higher frequency of complications [
         <a href="#rid82">
          82,83
         </a>
         ]. Some surgeons will not perform fundoplications on patients with a significantly elevated body mass index. However, children without underlying disorders also may have poor outcomes. (See
         <a class="local">
          'Relative contraindications'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3792841577">
         <span class="h2">
          Other surgical interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other techniques such as endoscopic radiofrequency ablation of the lower esophageal sphincter, endoscopic full-thickness fundoplication, and total esophagogastric disconnection have been described, primarily in adults. None of these techniques is recommended at this time for primary therapy of GERD in children [
         <a href="#rid1">
          1
         </a>
         ]. Total esophagogastric disconnection may be appropriate as a "rescue" procedure for selected children with neurologic impairment who have failed fundoplication [
         <a href="#rid1">
          1,4,116
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2496295845">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114786.html" rel="external">
          "Society guideline links: Gastroesophageal reflux in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16965.html" rel="external">
          "Patient education: Acid reflux and GERD in children and teens (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1175.html" rel="external">
          "Patient education: Gastroesophageal reflux disease in children and adolescents (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/1183.html" rel="external">
          "Patient education: Acid reflux (gastroesophageal reflux) in babies (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions
         </strong>
         – Gastroesophageal reflux (GER) is a normal physiologic process that occurs in healthy infants, children, and adults. In contrast, GER disease (GERD) occurs when the reflux episodes are associated with symptoms or complications. (See
         <a class="local">
          'Definitions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment approach
         </strong>
         – Our suggested approach depends on the patient's characteristics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Heartburn
         </strong>
         – For children or adolescents with mild or infrequent heartburn (averaging once a week or less), we suggest a trial of lifestyle changes (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Occasional use of antacids or histamine type 2 receptor antagonists (H2RAs) is acceptable for short-term relief of symptoms  (
         <a class="graphic graphic_algorithm graphicRef117377" href="/z/d/graphic/117377.html" rel="external">
          algorithm 1
         </a>
         ). If the heartburn symptoms are moderate or severe, or fail to respond to lifestyle changes, we recommend a trial of acid-suppression therapy (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). We generally prefer a proton pump inhibitor (PPI); an H2RA is a reasonable alternative but may lose efficacy over time. A typical trial duration is four to eight weeks. (See
         <a class="local">
          'Heartburn'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Patients with alarm symptoms (dysphagia, odynophagia, weight loss, hematemesis, or recurrent vomiting), or those with persistent or recurrent symptoms on a PPI, should be referred to a gastroenterologist for an upper endoscopy with biopsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Esophagitis
         </strong>
         – For children with endoscopically documented peptic esophagitis, we recommend treatment with an acid-suppressing medication  (
         <a class="graphic graphic_algorithm graphicRef117378" href="/z/d/graphic/117378.html" rel="external">
          algorithm 2
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). We also suggest a concurrent trial of lifestyle changes (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For initial treatment, we suggest a PPI rather than an H2RA (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Younger children appear to metabolize PPIs more rapidly and may require higher per-kilogram dosing than older individuals  (
         <a class="graphic graphic_table graphicRef55435" href="/z/d/graphic/55435.html" rel="external">
          table 1
         </a>
         ). Further evaluation and treatment depends on the initial severity of the esophagitis and on the response to treatment. (See
         <a class="local">
          'Esophagitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dysphagia
         </strong>
         – Dysphagia (difficulty swallowing) may be caused by GERD but also may have other causes, such as eosinophilic esophagitis (EoE), esophageal dysmotility, or foreign body. Children or adolescents with odynophagia (pain with swallowing) also should be evaluated for pill esophagitis and infectious esophagitis. Children with dysphagia should undergo an evaluation for other causes, including endoscopy, rather than empiric treatment for GER. (See
         <a class="local">
          'Dysphagia or odynophagia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5892.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents", section on 'Dysphagia or odynophagia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Asthma
         </strong>
         – For children with asthma and clinical or laboratory evidence of GER, asthma control may improve with acid-suppressing medication, but it is difficult to predict who will be responders. Therefore, we suggest a three-month trial of a PPI for patients with persistent moderate to severe asthma (particularly, nocturnal wheezing)
         <strong>
          and
         </strong>
         frequent heartburn or regurgitation suggesting GERD (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Asthma with gastroesophageal reflux'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment options
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lifestyle changes
         </strong>
         – Lifestyle changes that may reduce GER include weight management in overweight patients; cessation of smoking or vaping; elevation of the head of bed; and avoidance of chocolate, caffeine, spicy foods, alcohol, and other foods that exacerbate symptoms. Lifestyle changes may be used as an initial approach to treatment for children and adolescents with mild or infrequent symptoms of GER, or as an adjunct to pharmacologic treatment in patients with moderate or severe symptoms suggestive of GERD. (See
         <a class="local">
          'Lifestyle changes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pharmacotherapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Acid-suppressing medications are reasonably safe and effective for the treatment of established acid-related GERD. PPI medications are the most effective for short- or long-term acid suppression but also are associated with acid rebound on discontinuation, as well as some adverse effects with chronic use. H2RAs appear to be somewhat less effective than PPIs but are a reasonable alternative for short-term use. (See
         <a class="local">
          'Proton pump inhibitors'
         </a>
         above and
         <a class="local">
          'Histamine type 2 receptor antagonists'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We do
         <strong>
          not
         </strong>
         recommend using prokinetic agents for the routine treatment of children with GER or GERD (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Available prokinetic agents either have limited efficacy or significant safety concerns. (See
         <a class="local">
          'Prokinetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Surgery
         </strong>
         – Antireflux surgery (fundoplication) is an option for children with chronic esophagitis that is refractory to PPI treatment but must be undertaken with caution because of substantial failure rates and complications including persistent retching. Surgery should be approached with particular caution in children with neurologic impairment and/or pulmonary disease thought to be related to aspiration. (See
         <a class="local">
          'Surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lightdale JR, Gremse DA, Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics 2013; 131:e1684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies I, Burman-Roy S, Murphy MS, Guideline Development Group. Gastro-oesophageal reflux disease in children: NICE guidance. BMJ 2015; 350:g7703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano C, van Wynckel M, Hulst J, et al. European Society for Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for the Evaluation and Treatment of Gastrointestinal and Nutritional Complications in Children With Neurological Impairment. J Pediatr Gastroenterol Nutr 2017; 65:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006; 64:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nikaki K, Rybak A, Nakagawa K, et al. Rumination Syndrome in Children Presenting With Refractory Gastroesophageal Reflux Symptoms. J Pediatr Gastroenterol Nutr 2020; 70:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev 2003; :CD001496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold BD. Asthma and gastroesophageal reflux disease in children: exploring the relationship. J Pediatr 2005; 146:S13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothenberg S, Cowles R. The effects of laparoscopic Nissen fundoplication on patients with severe gastroesophageal reflux disease and steroid-dependent asthma. J Pediatr Surg 2012; 47:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassall E. Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. J Pediatr 2005; 146:S3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang AB, Oppenheimer JJ, Kahrilas PJ, et al. Chronic Cough and Gastroesophageal Reflux in Children: CHEST Guideline and Expert Panel Report. Chest 2019; 156:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandolfino JE, Kahrilas PJ. Smoking and gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2000; 12:837.
          </a>
         </li>
         <li class="breakAll">
          U.S. Food and Drug Administration: Drugs@FDA Web site www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on July 16, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther 2014; 5:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tighe MP, Andrews E, Liddicoat I, et al. Pharmacological treatment of gastro-oesophageal reflux in children. Cochrane Database Syst Rev 2023; 8:CD008550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000; 137:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cucchiara S, Minella R, Iervolino C, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993; 69:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold BD, Gunasekaran T, Tolia V, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007; 45:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boccia G, Manguso F, Miele E, et al. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? Am J Gastroenterol 2007; 102:1291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Pol RJ, Smits MJ, van Wijk MP, et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics 2011; 127:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore DJ, Tao BS, Lines DR, et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003; 143:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009; 154:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winter H, Kum-Nji P, Mahomedy SH, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr 2010; 50:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litalien C, Théorêt Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005; 44:441.
          </a>
         </li>
         <li class="breakAll">
          Phillips JO, Parsons DS, Fitts SW. Flavored lansoprazole suspension in pediatric GERD. World congress of Pediatric Gastroenterology, Hepatology, and Nutrition 2000. Abstract 750966.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs 2003; 5:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jimenez J, Drees M, Loveridge-Lenza B, et al. Exposure to Gastric Acid-Suppression Therapy Is Associated With Health Care- and Community-Associated Clostridium difficile Infection in Children. J Pediatr Gastroenterol Nutr 2015; 61:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lassalle M, Zureik M, Dray-Spira R. Proton Pump Inhibitor Use and Risk of Serious Infections in Young Children. JAMA Pediatr 2023; 177:1028.
          </a>
         </li>
         <li class="breakAll">
          FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm (Accessed on February 08, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006; 117:e817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosh JR, Hassall E. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. J Pediatr Gastroenterol Nutr 2006; 43:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieczkowska A, Landowski P, Zagozdzon P, et al. Small Bowel Bacterial Overgrowth Associated with Persistence of Abdominal Symptoms in Children Treated with a Proton Pump Inhibitor. J Pediatr 2015; 166:1310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen R, Amirault J, Liu H, et al. Changes in gastric and lung microflora with acid suppression: acid suppression and bacterial growth. JAMA Pediatr 2014; 168:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail 2015; 37:1237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tjon JA, Pe M, Soscia J, Mahant S. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease. Pharmacotherapy 2013; 33:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malchodi L, Wagner K, Susi A, et al. Early Acid Suppression Therapy Exposure and Fracture in Young Children. Pediatrics 2019; 144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang YH, Wintzell V, Ludvigsson JF, et al. Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children. JAMA Pediatr 2020; 174:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleishman N, Richardson T, Attard T. The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors. J Pediatr Gastroenterol Nutr 2020; 70:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yanagihara GR, de Paiva AG, Neto MP, et al. Effects of long-term administration of omeprazole on bone mineral density and the mechanical properties of the bone. Rev Bras Ortop 2015; 50:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassall E, Owen D, Kerr W, et al. Gastric histology in children treated with proton pump inhibitors (PPIs) long-term. Gastroenterology 2008; 134:A174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Björnsson E, Abrahamsson H, Simrén M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 24:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cucchiara S, Gobio-Casali L, Balli F, et al. Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study. J Pediatr Gastroenterol Nutr 1989; 8:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simeone D, Caria MC, Miele E, Staiano A. Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. J Pediatr Gastroenterol Nutr 1997; 25:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           See MC, Birnbaum AH, Schechter CB, et al. Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. Dig Dis Sci 2001; 46:985.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration News Release, 4/1/2020. FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine (Accessed on April 02, 2020).
         </li>
         <li class="breakAll">
          US Food and Drug Administration: Information about nitrosamine impurities in medications. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications (Accessed on April 21, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pivnick EK, Kerr NC, Kaufman RA, et al. Rickets secondary to phosphate depletion. A sequela of antacid use in infancy. Clin Pediatr (Phila) 1995; 34:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cucchiara S, Staiano A, Romaniello G, et al. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child 1984; 59:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iacono G, Carroccio A, Montalto G, et al. [Magnesium hydroxide and aluminum hydroxide in the treatment of gastroesophageal reflux]. Minerva Pediatr 1991; 43:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsou VM, Young RM, Hart MH, Vanderhoof JA. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum. Pediatrics 1991; 87:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodard-Knight L, Fudge A, Teubner J, Simmer K. Aluminium absorption and antacid therapy in infancy. J Paediatr Child Health 1992; 28:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sedman A. Aluminum toxicity in childhood. Pediatr Nephrol 1992; 6:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson RF, Casavant MJ, Nahata MC, Mahan JD. Metabolic bone disease after chronic antacid administration in an infant. Ann Pharmacother 2004; 38:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics 2006; 118:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maclennan S, Augood C, Cash-Gibson L, et al. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev 2010; :CD002300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol 2005; 59:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tighe MP, Afzal NA, Bevan A, Beattie RM. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. Paediatr Drugs 2009; 11:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vadlamudi NB, Hitch MC, Dimmitt RA, Thame KA. Baclofen for the treatment of pediatric GERD. J Pediatr Gastroenterol Nutr 2013; 57:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Omari TI, Benninga MA, Sansom L, et al. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr 2006; 149:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawai M, Kawahara H, Hirayama S, et al. Effect of baclofen on emesis and 24-hour esophageal pH in neurologically impaired children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2004; 38:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract 2014; 2014:307805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon B, Ravelli GP, Goffin H. Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1996; 10:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Argüelles-Martin F, Gonzalez-Fernandez F, Gentles MG. Sucralfate versus cimetidine in the treatment of reflux esophagitis in children. Am J Med 1989; 86:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment Pharmacol Ther 1998; 12:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greally P, Hampton FJ, MacFadyen UM, Simpson H. Gaviscon and Carobel compared with cisapride in gastro-oesophageal reflux. Arch Dis Child 1992; 67:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buts JP, Barudi C, Otte JB. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. Eur J Pediatr 1987; 146:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forbes D, Hodgson M, Hill R. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. J Pediatr Gastroenterol Nutr 1986; 5:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pouchain D, Bigard MA, Liard F, et al. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. BMC Gastroenterol 2012; 12:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vemulapalli R. Diet and lifestyle modifications in the management of gastroesophageal reflux disease. Nutr Clin Pract 2008; 23:293.
          </a>
         </li>
         <li class="breakAll">
          National Center for Complementary and Integrative Health. Available at: https://nccih.nih.gov/ (Accessed on December 20, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aumar M, Lalanne A, Guimber D, et al. Influence of Percutaneous Endoscopic Gastrostomy on Gastroesophageal Reflux Disease in Children. J Pediatr 2018; 197:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnhart DC, Hall M, Mahant S, et al. Effectiveness of fundoplication at the time of gastrostomy in infants with neurological impairment. JAMA Pediatr 2013; 167:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yap BK, Nah SA, Chen Y, Low Y. Fundoplication with gastrostomy vs gastrostomy alone: a systematic review and meta-analysis of outcomes and complications. Pediatr Surg Int 2017; 33:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sulaeman E, Udall JN Jr, Brown RF, et al. Gastroesophageal reflux and Nissen fundoplication following percutaneous endoscopic gastrostomy in children. J Pediatr Gastroenterol Nutr 1998; 26:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slater BJ, Dirks RC, McKinley SK, et al. SAGES guidelines for the surgical treatment of gastroesophageal reflux (GERD). Surg Endosc 2021; 35:4903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards CA. Postfundoplication retching: Strategies for management. J Pediatr Surg 2020; 55:1779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassall E. Outcomes of fundoplication: causes for concern, newer options. Arch Dis Child 2005; 90:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathei J, Coosemans W, Nafteux P, et al. Laparoscopic Nissen fundoplication in infants and children: analysis of 106 consecutive patients with special emphasis in neurologically impaired vs. neurologically normal patients. Surg Endosc 2008; 22:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez DA, Ginn-Pease ME, Caniano DA. Sequelae of antireflux surgery in profoundly disabled children. J Pediatr Surg 1992; 27:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith CD, Othersen HB Jr, Gogan NJ, Walker JD. Nissen fundoplication in children with profound neurologic disability. High risks and unmet goals. Ann Surg 1992; 215:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin JL, Rigdon J, Van Haren K, et al. Gastrostomy Tubes Placed in Children With Neurologic Impairment: Associated Morbidity and Mortality. J Child Neurol 2021; 36:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards CA, Carr D, Spitz L, et al. Nissen-type fundoplication and its effects on the emetic reflex and gastric motility in the ferret. Neurogastroenterol Motil 2000; 12:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards CA, Andrews PL, Spitz L, Milla PJ. Nissen fundoplication may induce gastric myoelectrical disturbance in children. J Pediatr Surg 1998; 33:1801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knatten CK, Fyhn TJ, Edwin B, et al. Thirty-day outcome in children randomized to open and laparoscopic Nissen fundoplication. J Pediatr Surg 2012; 47:1990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papandria D, Goldstein SD, Salazar JH, et al. A randomized trial of laparoscopic versus open Nissen fundoplication in children under two years of age. J Pediatr Surg 2015; 50:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kubiak R, Böhm-Sturm E, Svoboda D, Wessel LM. Comparison of long-term outcomes between open and laparoscopic Thal fundoplication in children. J Pediatr Surg 2014; 49:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ru W, Wu P, Feng S, et al. Laparoscopic versus open Nissen fundoplication in children: A systematic review and meta-analysis. J Pediatr Surg 2016; 51:1731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McHoney M, Wade AM, Eaton S, et al. Clinical outcome of a randomized controlled blinded trial of open versus laparoscopic Nissen fundoplication in infants and children. Ann Surg 2011; 254:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz DM, Gibbons TE, Heiss K, et al. Antireflux surgery outcomes in pediatric gastroesophageal reflux disease. Am J Gastroenterol 2005; 100:1844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kane TD, Brown MF, Chen MK, Members of the APSA New Technology Committee. Position paper on laparoscopic antireflux operations in infants and children for gastroesophageal reflux disease. American Pediatric Surgery Association. J Pediatr Surg 2009; 44:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fyhn TJ, Knatten CK, Edwin B, et al. Randomized Controlled Trial of Laparoscopic and Open Nissen Fundoplication in Children. Ann Surg 2015; 261:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauritz FA, Conchillo JM, van Heurn LWE, et al. Effects and efficacy of laparoscopic fundoplication in children with GERD: a prospective, multicenter study. Surg Endosc 2017; 31:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilger MA, Yeh C, Chiang J, et al. Outcomes of surgical fundoplication in children. Clin Gastroenterol Hepatol 2004; 2:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung KM, Tse HW, Tse PW, Chan KH. Nissen fundoplication and gastrostomy in severely neurologically impaired children with gastroesophageal reflux. Hong Kong Med J 2006; 12:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor LA, Weiner T, Lacey SR, Azizkhan RG. Chronic lung disease is the leading risk factor correlating with the failure (wrap disruption) of antireflux procedures in children. J Pediatr Surg 1994; 29:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baerg J, Thorpe D, Bultron G, et al. A multicenter study of the incidence and factors associated with redo Nissen fundoplication in children. J Pediatr Surg 2013; 48:1306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldin AB, Sawin R, Seidel KD, Flum DR. Do antireflux operations decrease the rate of reflux-related hospitalizations in children? Pediatrics 2006; 118:2326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srivastava R, Berry JG, Hall M, et al. Reflux related hospital admissions after fundoplication in children with neurological impairment: retrospective cohort study. BMJ 2009; 339:b4411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maret-Ouda J, Santoni G, Artama M, et al. Aspiration pneumonia after antireflux surgery among neurologically impaired children with GERD. J Pediatr Surg 2020; 55:2408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boesch RP, Acton JD. Outcomes of fundoplication in children with cystic fibrosis. J Pediatr Surg 2007; 42:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalla Vecchia LK, Grosfeld JL, West KW, et al. Reoperation after Nissen fundoplication in children with gastroesophageal reflux: experience with 130 patients. Ann Surg 1997; 226:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bensoussan AL, Yazbeck S, Carceller-Blanchard A. Results and complications of Toupet partial posterior wrap: 10 years' experience. J Pediatr Surg 1994; 29:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fonkalsrud EW, Ashcraft KW, Coran AG, et al. Surgical treatment of gastroesophageal reflux in children: a combined hospital study of 7467 patients. Pediatrics 1998; 101:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fonkalsrud EW, Bustorff-Silva J, Perez CA, et al. Antireflux surgery in children under 3 months of age. J Pediatr Surg 1999; 34:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber TR. Toupét fundoplication for gastroesophageal reflux in childhood. Arch Surg 1999; 134:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tovar JA, Luis AL, Encinas JL, et al. Pediatric surgeons and gastroesophageal reflux. J Pediatr Surg 2007; 42:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kristensen C, Avitsland T, Emblem R, et al. Satisfactory long-term results after Nissen fundoplication. Acta Paediatr 2007; 96:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harnsberger JK, Corey JJ, Johnson DG, Herbst JJ. Long-term follow-up of surgery for gastroesophageal reflux in infants and children. J Pediatr 1983; 102:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Loughlin EV, Somerville H, Shun A, et al. Antireflux surgery in children with neurological impairment: caregiver perceptions and complications. J Pediatr Gastroenterol Nutr 2013; 56:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards CA, Milla PJ, Andrews PL, Spitz L. Retching and vomiting in neurologically impaired children after fundoplication: predictive preoperative factors. J Pediatr Surg 2001; 36:1401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Battaglia S, Orizio P, Boroni G, et al. Total Oesophagogastric Dissociation in Neurologically Impaired Children: 18 Years' Experience and Long-term Follow-up. J Pediatr Gastroenterol Nutr 2020; 70:457.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5900 Version 67.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29373438" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23629618" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Gastroesophageal reflux: management guidance for the pediatrician.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25591811" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Gastro-oesophageal reflux disease in children: NICE guidance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28737572" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : European Society for Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for the Evaluation and Treatment of Gastrointestinal and Nutritional Complications in Children With Neurological Impairment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21477849" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Eosinophilic esophagitis: updated consensus recommendations for children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16923475" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32079888" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Rumination Syndrome in Children Presenting With Refractory Gastroesophageal Reflux Symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12804410" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Gastro-oesophageal reflux treatment for asthma in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15758898" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Asthma and gastroesophageal reflux disease in children: exploring the relationship.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22703777" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The effects of laparoscopic Nissen fundoplication on patients with severe gastroesophageal reflux disease and steroid-dependent asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15758900" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31002783" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Chronic Cough and Gastroesophageal Reflux in Children: CHEST Guideline and Expert Panel Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16682569" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10958210" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Smoking and gastro-oesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10958210" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Smoking and gastro-oesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9178669" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24868486" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37635269" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pharmacological treatment of gastro-oesophageal reflux in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11113836" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8285777" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18030228" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17319927" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21464183" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12970637" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19054529" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20400912" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15871633" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pharmacokinetics of proton pump inhibitors in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15871633" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pharmacokinetics of proton pump inhibitors in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12513104" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The use of proton pump inhibitors in children: a comprehensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25806678" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Exposure to Gastric Acid-Suppression Therapy Is Associated With Health Care- and Community-Associated Clostridium difficile Infection in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37578761" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Proton Pump Inhibitor Use and Risk of Serious Infections in Young Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37578761" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Proton Pump Inhibitor Use and Risk of Serious Infections in Young Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16651285" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17033535" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25681195" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Small Bowel Bacterial Overgrowth Associated with Persistence of Abdominal Symptoms in Children Treated with a Proton Pump Inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25133779" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Changes in gastric and lung microflora with acid suppression: acid suppression and bacterial growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26108134" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23712734" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31175146" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Early Acid Suppression Therapy Exposure and Fracture in Young Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32176276" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32443038" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26229922" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Effects of long-term administration of omeprazole on bone mineral density and the mechanical properties of the bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10734017" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Gastric histology in children treated with proton pump inhibitors (PPIs) long-term
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19362552" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16948806" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2651632" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9226527" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11341669" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11341669" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11341669" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7729110" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Rickets secondary to phosphate depletion. A sequela of antacid use in infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6385868" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1798406" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : [Magnesium hydroxide and aluminum hydroxide in the treatment of gastroesophageal reflux].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1987526" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1605980" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Aluminium absorption and antacid therapy in infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1498007" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Aluminum toxicity in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14742764" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Metabolic bone disease after chronic antacid administration in an infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16882832" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20393933" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Cisapride treatment for gastro-oesophageal reflux in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15948939" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19445547" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23838820" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Baclofen for the treatment of pediatric GERD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17011315" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15076634" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effect of baclofen on emesis and 24-hour esophageal pH in neurologically impaired children with gastroesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25389436" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8791975" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2735338" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Sucralfate versus cimetidine in the treatment of reflux esophagitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9692690" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1599300" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Gaviscon and Carobel compared with cisapride in gastro-oesophageal reflux.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3032640" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3016226" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The effects of gaviscon and metoclopramide in gastroesophageal reflux in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22361121" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Gaviscon®vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18595862" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Diet and lifestyle modifications in the management of gastroesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18595862" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Diet and lifestyle modifications in the management of gastroesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29655862" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Influence of Percutaneous Endoscopic Gastrostomy on Gastroesophageal Reflux Disease in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23921627" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Effectiveness of fundoplication at the time of gastrostomy in infants with neurological impairment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27889821" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Fundoplication with gastrostomy vs gastrostomy alone: a systematic review and meta-analysis of outcomes and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9523860" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Gastroesophageal reflux and Nissen fundoplication following percutaneous endoscopic gastrostomy in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34279710" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : SAGES guidelines for the surgical treatment of gastroesophageal reflux (GERD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32409173" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Postfundoplication retching: Strategies for management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16177161" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Outcomes of fundoplication: causes for concern, newer options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17943378" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Laparoscopic Nissen fundoplication in infants and children: analysis of 106 consecutive patients with special emphasis in neurologically impaired vs. neurologically normal patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1532982" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Sequelae of antireflux surgery in profoundly disabled children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1632687" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Nissen fundoplication in children with profound neurologic disability. High risks and unmet goals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33750232" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Gastrostomy Tubes Placed in Children With Neurologic Impairment: Associated Morbidity and Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10652115" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Nissen-type fundoplication and its effects on the emetic reflex and gastric motility in the ferret.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9869055" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Nissen fundoplication may induce gastric myoelectrical disturbance in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23163988" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Thirty-day outcome in children randomized to open and laparoscopic Nissen fundoplication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25638616" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : A randomized trial of laparoscopic versus open Nissen fundoplication in children under two years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24952790" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Comparison of long-term outcomes between open and laparoscopic Thal fundoplication in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27516174" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Laparoscopic versus open Nissen fundoplication in children: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21725231" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Clinical outcome of a randomized controlled blinded trial of open versus laparoscopic Nissen fundoplication in infants and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16086723" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Antireflux surgery outcomes in pediatric gastroesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19433194" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Position paper on laparoscopic antireflux operations in infants and children for gastroesophageal reflux disease. American Pediatric Surgery Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26291953" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Randomized Controlled Trial of Laparoscopic and Open Nissen Fundoplication in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27369283" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Effects and efficacy of laparoscopic fundoplication in children with GERD: a prospective, multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15551250" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Outcomes of surgical fundoplication in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16912355" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Nissen fundoplication and gastrostomy in severely neurologically impaired children with gastroesophageal reflux.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8176586" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Chronic lung disease is the leading risk factor correlating with the failure (wrap disruption) of antireflux procedures in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23845623" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : A multicenter study of the incidence and factors associated with redo Nissen fundoplication in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17142515" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Do antireflux operations decrease the rate of reflux-related hospitalizations in children?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19923145" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Reflux related hospital admissions after fundoplication in children with neurological impairment: retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32037217" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Aspiration pneumonia after antireflux surgery among neurologically impaired children with GERD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17706493" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Outcomes of fundoplication in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9339938" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Reoperation after Nissen fundoplication in children with gastroesophageal reflux: experience with 130 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7807348" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Results and complications of Toupet partial posterior wrap: 10 years' experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9481007" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Surgical treatment of gastroesophageal reflux in children: a combined hospital study of 7467 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10235314" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Antireflux surgery in children under 3 months of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10401821" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Toupét fundoplication for gastroesophageal reflux in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17270535" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Pediatric surgeons and gastroesophageal reflux.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17462062" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Satisfactory long-term results after Nissen fundoplication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6834183" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Long-term follow-up of surgery for gastroesophageal reflux in infants and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22785414" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Antireflux surgery in children with neurological impairment: caregiver perceptions and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11528615" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Retching and vomiting in neurologically impaired children after fundoplication: predictive preoperative factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31913925" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Total Oesophagogastric Dissociation in Neurologically Impaired Children: 18 Years' Experience and Long-term Follow-up.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
